Rome Therapeutics

Executive Summary

Rome Therapeutics is pioneering the exploration of the 'dark genome'—the extensive, repetitive regions of human DNA derived from ancient viral infections and other transposable elements. The company believes these overlooked genomic sequences play critical roles in autoimmune diseases and cancer, and has developed a platform to identify and validate drug targets within this uncharted territory. By focusing on first-in-class medicines, Rome aims to unlock a novel therapeutic axis that has been largely inaccessible to conventional drug discovery approaches. Founded in 2019 and based in Cambridge, MA, the company has raised $72 million to advance its preclinical programs and platform development. Currently in the preclinical stage, Rome is prioritizing lead optimization for its most advanced candidates, with plans to select a development candidate and initiate IND-enabling studies within the next 12-18 months. The company's success hinges on demonstrating that targeting the dark genome can yield safe and effective therapies, a hypothesis that remains unproven clinically. However, the potential for a new class of drugs addressing high-unmet-need indications provides significant upside. Near-term milestones include platform validation data, potential Series B/C financing, and progression toward a first IND filing, likely targeting an autoimmune indication first.

Upcoming Catalysts (preview)

• Q1 2027Lead candidate selection and IND-enabling studies initiation40% success
• Q3 2026Platform validation data publication or presentation at major conference70% success
• Q2 2026Series B or C financing round to fund pipeline progression75% success